The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis
Open accessAbstract
The expression of Programmed cell Death Ligand 1 (PD-L1) is observed in many malignant tumors and is associated with poor prognosis including Gastric Cancer (GC). The relationship between PD-L1 expression and prognosis, however, is controversial in GC. This paper purports to use a meta-analysis to investigate the relationship between PD-L1 expression and prognosis in GC. For this study, the following databases were searched for articles published from June 2003 until February 2017: PubMed, EBSCO, Web of Science and Cochrane Library. The baseline information extracted were: authors, year of publication, country where the study was performed, study design, sample size, follow-up time, baseline characteristics of the study population, pathologic data, overall survival (OS). A total of 15 eligible studies covering 3291 patients were selected for a meta-analysis based on specified inclusion and exclusion criteria. The analysis showed that the expression level of PD-L1 was associated with the overall survival in GC (Hazard Ratio, HR = 1.46, 95%CI = 1.08-1.98, P = 0.01, random-effect). In addition to the above, subgroup analysis showed that GC patients with deeper tumor infiltration, positive lymph-node metastasis, positive venous invasion, Epstein-Barr virus infection positive (EBV+), Microsatellite Instability (MSI) are more likely to expression PD-L1. The results of this meta-analysis suggest that GC patients, specifically EBV+ and MSI, may be prime candidates for PD-1 directed therapy. These findings support anti-PD-L1/PD-1 antibodies as a kind of immunotherapy which is promising for GC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Global cancer statistics, 2012
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet‐Tieulent, J., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21262 · Cited by 26,850
PRISMA-P Group, Moher, D., Shamseer, L., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., Shekelle, P., & Stewart, L. A. (2015) · Systematic Reviews · doi:10.1186/2046-4053-4-1 · Cited by 26,223
Dermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,196
Stang, A. (2010) · European Journal of Epidemiology · doi:10.1007/s10654-010-9491-z · Cited by 17,396
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2010) · International Journal of Surgery · doi:10.1016/j.ijsu.2010.02.007 · Cited by 12,156
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells
Fontenot, J. D., Gavin, M. A., & Rudensky, A. Y. (2003) · Nature Immunology · doi:10.1038/ni904 · Cited by 7,745
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Comprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Regulatory T Cells and Immune Tolerance
Sakaguchi, S., Yamaguchi, T., Nomura, T., & Ono, M. (2008) · Cell · doi:10.1016/j.cell.2008.05.009 · Cited by 5,325
Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Dols, M. C., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,675
Fuchs, C. S., Tomasek, J., Yong, C. J., Dumitru, F., Passalacqua, R., Goswami, C., Safran, H., dos Santos, L. V., Aprile, G., Ferry, D. R., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61719-5 · Cited by 2,188
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Francisco, L. M., Salinas, V. H., Brown, K. E., Vanguri, V. K., Freeman, G. J., Kuchroo, V. K., & Sharpe, A. H. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090847 · Cited by 2,079
Inhibitory B7-family molecules in the tumour microenvironment
Zou, W., & Chen, L. (2008) · Nature Reviews Immunology · doi:10.1038/nri2326 · Cited by 1,608
The appropriateness of asymmetry tests for publication bias in meta-analyses: A large survey
Ioannidis, J. P. A., & Trikalinos, T. A. (2007) · Canadian Medical Association Journal · doi:10.1503/cmaj.060410 · Cited by 1,052
Lordick, F., Kang, Y.-K., Chung, H.-C., Salman, P., Oh, S. C., Bodoky, G., Kurteva, G., Volovat, C., Moiseyenko, V. M., Gorbunova, V., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70102-5 · Cited by 833
Waddell, T., Chau, I., Cunningham, D., Gonzalez, D., Okines, A. F. C., Wotherspoon, A., Saffery, C., Middleton, G., Wadsley, J., Ferry, D., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70096-2 · Cited by 725
Mace, T. A., Shakya, R., Pitarresi, J. R., Swanson, B., McQuinn, C. W., Loftus, S., Nordquist, E., Cruz-Monserrate, Z., Yu, L., Young, G., et al. (2018) · Gut · doi:10.1136/gutjnl-2016-311585 · Cited by 539
Self-citationWu, C., Zhu, Y., Jiang, J., Zhao, J., Zhang, X.-G., & Xu, N. (2006) · Acta Histochemica · doi:10.1016/j.acthis.2006.01.003 · Cited by 495
Van Cutsem, E., de Haas, S., Kang, Y.-K., Ohtsu, A., Tebbutt, N. C., Ming Xu, J., Peng Yong, W., Langer, B., Delmar, P., Scherer, S. J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.9824 · Cited by 477
PD-L1 and Survival in Solid Tumors: A Meta-Analysis
Wu, P., Wu, D., Li, L., Chai, Y., & Huang, J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0131403 · Cited by 352
Hartling, L., Featherstone, R., Nuspl, M., Shave, K., Dryden, D. M., & Vandermeer, B. (2017) · BMC Medical Research Methodology · doi:10.1186/s12874-017-0347-z · Cited by 324
Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers
Derks, S., Liao, X., Chiaravalli, A. M., Xu, X., Camargo, M. C., Solcia, E., Sessa, F., Fleitas, T., Freeman, G. J., Rodig, S. J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9076 · Cited by 308
Blockade of PD‐L1 (B7‐H1) augments human tumor‐specific T cell responses in vitro
Blank, C., Kuball, J., Voelkl, S., Wiendl, H., Becker, B., Walter, B., Majdic, O., Gajewski, T. F., Theobald, M., Andreesen, R., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.21775 · Cited by 297
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma
Choueiri, T. K., Fishman, M. N., Escudier, B., McDermott, D. F., Drake, C. G., Kluger, H., Stadler, W. M., Perez-Gracia, J. L., McNeel, D. G., Curti, B., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2839 · Cited by 295
PD-L1 is an independent prognostic predictor in gastric cancer of Western patients
Böger, C., Behrens, H.-M., Mathiak, M., Krüger, S., Kalthoff, H., & Röcken, C. (2016) · Oncotarget · doi:10.18632/oncotarget.8169 · Cited by 287
Kim, J. W., Nam, K. H., Ahn, S.-H., Park, D. J., Kim, H.-H., Kim, S. H., Chang, H., Lee, J.-O., Kim, Y. J., Lee, H. S., et al. (2016) · Gastric Cancer · doi:10.1007/s10120-014-0440-5 · Cited by 250
Kawazoe, A., Kuwata, T., Kuboki, Y., Shitara, K., Nagatsuma, A. K., Aizawa, M., Yoshino, T., Doi, T., Ohtsu, A., & Ochiai, A. (2017) · Gastric Cancer · doi:10.1007/s10120-016-0631-3 · Cited by 225
Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer
Qing, Y., Li, Q., Ren, T., Xia, W., Peng, Y., Liu, G. L., Luo, H., Yang, Y., Dai, X. Y., Zhou, S.-F., et al. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s75152 · Cited by 179
Saito, R., Abe, H., Kunita, A., Yamashita, H., Seto, Y., & Fukayama, M. (2017) · Modern Pathology · doi:10.1038/modpathol.2016.202 · Cited by 158
Ma, C., Patel, K., Singhi, A. D., Ren, B., Zhu, B., Shaikh, F. Y., & Sun, W. (2016) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000698 · Cited by 157
Zhang, M., Dong, Y., Liu, H., Wang, Y., Zhao, S., Xuan, Q., Wang, Y., & Zhang, Q. (2016) · Scientific Reports · doi:10.1038/srep37933 · Cited by 154
Eto, S., Yoshikawa, K., Nishi, M., Higashijima, J., Tokunaga, T., Nakao, T., Kashihara, H., Takasu, C., Iwata, T., & Shimada, M. (2015) · Gastric Cancer · doi:10.1007/s10120-015-0519-7 · Cited by 148
Hou, J., Yu, Z., Xiang, R., Li, C., Wang, L., Chen, S., Li, Q., Chen, M., & Wang, L. (2014) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2014.03.005 · Cited by 137
Self-citationGeng, Y., Wang, H., Chang-qing, L., Li, Q., Xu, B., Jiang, J., & Wu, C. (2014) · International Journal of Clinical Oncology · doi:10.1007/s10147-014-0701-7 · Cited by 124
Zhang, L., Qiu, M., Jin, Y., Ji, J., Li, B., Wang, X., Yan, S., Xu, R., & Yang, D. (2015) · PubMed · Cited by 97
Self-citationDai, C., Geng, R., Wang, C., Wong, A., Qing, M., Hu, J., Sun, Y. L., Lo, A. W. I., & Li, J. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2016.09.004 · Cited by 69
PUBLICATION BIAS AND META-ANALYSES: A Practical Example
Burdett, S., Stewart, L. A., & Tierney, J. F. (2003) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462303000126 · Cited by 67
PD-L1 expression is associated with massive lymphocyte infiltration and histology in gastric cancer
Li, Z., Lai, Y., Sun, L. N., Zhang, X., Liu, R., Feng, G., Zhou, L., Jia, L., Huang, X., Kang, Q., et al. (2016) · Human Pathology · doi:10.1016/j.humpath.2016.05.012 · Cited by 63
Chang, H., Jung, W. Y., Kang, Y., Lee, H., Kim, A., Kim, H. K., Shin, B. K., & Kim, B. (2016) · Oncotarget · doi:10.18632/oncotarget.12603 · Cited by 52
Clinicopathologic Significance and Prognostic Value of B7 Homolog 1 in Gastric Cancer
Xu, F., Feng, G., Zhao, H., Liu, F., Xu, L., Wang, Q., & An, G. (2015) · Medicine · doi:10.1097/md.0000000000001911 · Cited by 26
Kang, H. J., Lee, I., Park, Y.-S., Ho, W. J., Sohn, D., Ahn, J.-Y., Yook, J. H., & Kim, B. S. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-016-5284-2 · Cited by 18
Liu, X., Yang, Z., Latchoumanin, O., & Qiao, L. (2016) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x16658251 · Cited by 15
Cited by
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Bang, Y.-J., Ruiz, E. Y., Van Cutsem, E., Lee, K.-W., Wyrwicz, L., Schenker, M., Alsina, M., Ryu, M.-H., Chung, H.-C., Evesque, L., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy264 · Cited by 501
Biomarkers of gastric cancer: Current topics and future perspective
Matsuoka, T., & Yashiro, M. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i26.2818 · Cited by 476
Signaling pathways and therapeutic interventions in gastric cancer
Lei, Z.-N., Teng, Q.-X., Tian, Q., Chen, W., Xie, Y., Wu, K., Zeng, Q., Zeng, L., Pan, Y., Chen, Z.-S., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01190-w · Cited by 322
Estimating the global burden of Epstein–Barr virus-related cancers
Wong, Y., Meehan, M. T., Burrows, S. R., Doolan, D. L., & Miles, J. J. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03824-y · Cited by 314
Metadata
- Authors
- Gu, L., Chen, M., Guo, D., Zhu, H., Zhang, W., Pan, J., Zhong, X., Li, X., Qian, H., & Wang, X.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2017-08-10
- Volume
- 12
- Issue
- 8
- Pages
- e0182692
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2742446628
- Cited by
- 280
- References
- 48
- FWCI
- 2.47
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.